CN1303206C - 一种诱导干细胞向肝细胞定向分化的方法及肝细胞的用途 - Google Patents
一种诱导干细胞向肝细胞定向分化的方法及肝细胞的用途 Download PDFInfo
- Publication number
- CN1303206C CN1303206C CNB2004100864753A CN200410086475A CN1303206C CN 1303206 C CN1303206 C CN 1303206C CN B2004100864753 A CNB2004100864753 A CN B2004100864753A CN 200410086475 A CN200410086475 A CN 200410086475A CN 1303206 C CN1303206 C CN 1303206C
- Authority
- CN
- China
- Prior art keywords
- cell
- cells
- differentiation
- hgf
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims abstract description 24
- 230000001939 inductive effect Effects 0.000 title claims abstract description 12
- 210000005229 liver cell Anatomy 0.000 title abstract description 19
- 210000004027 cell Anatomy 0.000 claims abstract description 98
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims abstract description 53
- 230000004069 differentiation Effects 0.000 claims abstract description 43
- 210000003494 hepatocyte Anatomy 0.000 claims abstract description 18
- 210000004185 liver Anatomy 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 230000006698 induction Effects 0.000 claims abstract description 9
- 238000002054 transplantation Methods 0.000 claims abstract description 8
- 102000057308 human HGF Human genes 0.000 claims abstract description 7
- 210000004700 fetal blood Anatomy 0.000 claims description 23
- 210000004024 hepatic stellate cell Anatomy 0.000 claims description 14
- 239000011324 bead Substances 0.000 claims description 8
- 241001430294 unidentified retrovirus Species 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 230000002440 hepatic effect Effects 0.000 abstract description 3
- 230000001172 regenerating effect Effects 0.000 abstract description 3
- 210000004504 adult stem cell Anatomy 0.000 abstract description 2
- 210000002536 stromal cell Anatomy 0.000 abstract description 2
- 238000010353 genetic engineering Methods 0.000 abstract 2
- 238000007877 drug screening Methods 0.000 abstract 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 45
- 239000000047 product Substances 0.000 description 21
- 238000003757 reverse transcription PCR Methods 0.000 description 13
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 12
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 12
- 238000011010 flushing procedure Methods 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- 102000009027 Albumins Human genes 0.000 description 11
- 108010088751 Albumins Proteins 0.000 description 11
- 230000000763 evoking effect Effects 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 9
- 239000004202 carbamide Substances 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 8
- 108010066327 Keratin-18 Proteins 0.000 description 8
- 239000012228 culture supernatant Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 210000005087 mononuclear cell Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000283707 Capra Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 102100036912 Desmin Human genes 0.000 description 4
- 108010044052 Desmin Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 4
- 108010066302 Keratin-19 Proteins 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 210000005045 desmin Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 102100036774 Afamin Human genes 0.000 description 3
- 101710149366 Afamin Proteins 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000000432 density-gradient centrifugation Methods 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 102000012466 Cytochrome P450 1B1 Human genes 0.000 description 2
- 108050002014 Cytochrome P450 1B1 Proteins 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 208000034423 Delivery Diseases 0.000 description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 101000756643 Rattus norvegicus Actin, cytoplasmic 1 Proteins 0.000 description 2
- 101150052863 THY1 gene Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 101150033839 4 gene Proteins 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 101100260568 Mus musculus Thy1 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000625 blastula Anatomy 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
| 基因名称 | 引物序列 | 扩增片段长度(bp) |
| AFPAlbuminCK19CYP1B1α-tubulin | S:5′-TGCAGCCAAAGTGAAGAGGGAAGA-3′A:5′-CATAGCGAGCAGCCCAAAGAAGAA-3′S:5′-TGCTTGAATGTGCTGATGACAGGG-3′A:5′-AAGGCAAGTCAGCAGGCATCTCATC-3′S:5′-ATGGCCGAGCAGAACCGGAA-3′A:5′-CCATGAGCCGCTGGTACTCC-3′S:5′-GAGAACGTACCGGCCACTATCACT-3′A:5′-GTTAGGCCACTTCAGTGGGTCATGAT-3′S:5′-CACCCGTCTTCAGGGCTTCTTGGTTT-3′A:5′-CATTTCACCATCTGGTTGGCTGGCTC-3′ | 217162328357528 |
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100864753A CN1303206C (zh) | 2003-10-22 | 2004-10-21 | 一种诱导干细胞向肝细胞定向分化的方法及肝细胞的用途 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200310101869.7 | 2003-10-22 | ||
| CN200310101869 | 2003-10-22 | ||
| CNB2004100864753A CN1303206C (zh) | 2003-10-22 | 2004-10-21 | 一种诱导干细胞向肝细胞定向分化的方法及肝细胞的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1611599A CN1611599A (zh) | 2005-05-04 |
| CN1303206C true CN1303206C (zh) | 2007-03-07 |
Family
ID=34796274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100864753A Expired - Fee Related CN1303206C (zh) | 2003-10-22 | 2004-10-21 | 一种诱导干细胞向肝细胞定向分化的方法及肝细胞的用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1303206C (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101148656B (zh) * | 2006-09-18 | 2010-10-27 | 中国人民解放军军事医学科学院野战输血研究所 | 一种组织工程化肝单元的构建方法 |
| JP6076076B2 (ja) * | 2012-12-21 | 2017-02-08 | 日東電工株式会社 | 組織再生促進剤 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003014313A2 (en) * | 2001-08-06 | 2003-02-20 | Bresagen, Ltd. | Alternative compositions and methods for the culture of stem cells |
-
2004
- 2004-10-21 CN CNB2004100864753A patent/CN1303206C/zh not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003014313A2 (en) * | 2001-08-06 | 2003-02-20 | Bresagen, Ltd. | Alternative compositions and methods for the culture of stem cells |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1611599A (zh) | 2005-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1195055C (zh) | 从胎盘组织中提取造血干细胞用于建立造血干细胞库的新方法 | |
| CN101942413B (zh) | 出生缺陷细胞库及其构建方法 | |
| CN103800898B (zh) | 一种肿瘤特异性杀伤细胞制剂及其制备方法 | |
| CN1309180A (zh) | 用于来自脂肪组织的基质细胞的多中胚层谱系分化潜能和其用途 | |
| CN105985985A (zh) | Crispr技术编辑并用igf优化的异体间充质干细胞的制备方法及在治疗心梗中应用 | |
| WO2010040262A1 (zh) | 分离动物胚胎间质性干细胞并提取其分泌物的方法 | |
| US20220380733A1 (en) | Method for culturing urine-derived kidney stem cells and use thereof | |
| CN110675914A (zh) | 一种筛选肿瘤特异性t细胞及tcr的方法 | |
| CN109022362A (zh) | 一种高白细胞性白血病pdx模型的建立方法 | |
| CN102876630A (zh) | 一种高效分离和扩增人脐带血间充质干细胞的方法 | |
| CN110484504B (zh) | 一种用于免疫治疗原发性肝细胞肝癌的细胞亚群及其制备方法 | |
| CN117106724A (zh) | 一种h3k27m突变型脊髓胶质瘤细胞及其培养方法 | |
| CN109679902A (zh) | 一种基于cik免疫细胞的体外诱导扩增方法 | |
| CN1303206C (zh) | 一种诱导干细胞向肝细胞定向分化的方法及肝细胞的用途 | |
| CN115851577A (zh) | 一种基于单细胞的骨肉瘤类器官模型的构建方法 | |
| CN1837358A (zh) | 一种三维条件下扩增造血干细胞的方法 | |
| RU2012107674A (ru) | Биотрансплантат для восстановления объема костной ткани при дегенеративных заболеваниях и травматических повреждениях костей и способ его получения | |
| KR102736008B1 (ko) | 고순도 및 고효율의 자연살해세포 제조방법 및 이의 용도 | |
| CN114807031A (zh) | 一种人外周血免疫细胞库和干细胞库的构建方法 | |
| CN105316286A (zh) | 一种制备重组间充质干细胞的方法及其得到的重组间充质干细胞 | |
| CN108034634B (zh) | 一种从经血中分离宫内膜间充质干细胞的方法 | |
| CN116836933B (zh) | 肝胆癌类器官培养液、培养试剂组合及培养方法 | |
| CN101412987A (zh) | 体外骨髓间充质干细胞扩增方法 | |
| CN1306027C (zh) | 一种体外扩增γδT淋巴细胞的方法 | |
| CN104789529A (zh) | 促进小鼠骨髓造血干细胞体外克隆形成及分化能力的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20050504 Assignee: SOUTH CHINA CENTER FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE OF ACADEMY OF MILITARY MEDICAL SCIENCES Assignor: INSTITUE OF TRANSFUSION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PEOPLE'S LIBRATION ARMY OF CHINA Contract record no.: 2015990000123 Denomination of invention: Method for inducing stem cell to liver cell directional diferentiation and use of liver cell Granted publication date: 20070307 License type: Exclusive License Record date: 20150324 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070307 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |